[go: up one dir, main page]

WO2003061679A1 - Composition pour reguler la glycemie - Google Patents

Composition pour reguler la glycemie Download PDF

Info

Publication number
WO2003061679A1
WO2003061679A1 PCT/US2003/001786 US0301786W WO03061679A1 WO 2003061679 A1 WO2003061679 A1 WO 2003061679A1 US 0301786 W US0301786 W US 0301786W WO 03061679 A1 WO03061679 A1 WO 03061679A1
Authority
WO
WIPO (PCT)
Prior art keywords
ooomg
blood sugar
insulin
diabetes
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001786
Other languages
English (en)
Inventor
Dennis H. M. D. Harris
Robert Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2003061679A1 publication Critical patent/WO2003061679A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives

Definitions

  • This formulation may be used with or
  • Type 2 diabetes previously called “adult onset diabetes”
  • Type 2 a disease that, until several years ago, primarily occurred in overweight adults over 45
  • Type 2 diabetes are developing Type 2 diabetes.
  • the pancreas may be of Type 2 diabetes.
  • the pancreas may be of Type 2 diabetes.
  • Type 1 diabetes previously called "juvenile diabetes", in which the beta cells of the pancreas have been destroyed and
  • diabetes is believed to have multiple etiologies including, but not
  • the object of the present invention is to provide a unique combination of vitamins, minerals, herbs and other nutritional/nutraceutical
  • ingredients that will aid in the management of hyperglycemia and blood sugar dysregulation of any type, as well as aid in the improvement of cellular
  • This invention involves the novel and unique combination of nutritional/nutraceutical ingredients to be taken as an oral supplement for enhancing blood sugar regulation and controlling hyperglycemia,
  • hypoinsulinemia hyperinsulinemia and aspects of Syndrome X.
  • composition may further comprise a delivery form for these components, such as powder, liquid, spray, tablet, caplet, or aerosol.
  • Administration of the composition is anticipated to typically be via the oral route, but other forms of the composition may be delivered via the intramuscular, subcutaneous, intravenous, intranasal or sublingual routes.
  • the invention may also include ancillary ingredients such as coloring agents,
  • Insulin resistance is the central metabolic defect in a cluster of disorders now referred to as Syndrome X.
  • This cluster of diseases includes Type 2 diabetes mellitus and hyperinsulinemia.
  • French Lilac chemically known as guianidine, is particularly effective in reducing the blood glucose level utilizing a different mechanism. This herb
  • Non-insulin dependent diabetics are able to better maintain blood glucose levels closer to the
  • This invention is a unique combination of French lilac and other natural
  • the preferred embodiment is as follows, listed by amount:
  • a specific preferred embodiment shown to be effective comprises 100 mg French Lilac/Goat's Rue, 50 mg cinnamon, 100 mg American ginseng, 100 mg bitter melon, 200 mg Gymnema Sylvestre, 25 mg Garlic, 1 5 mg
  • Chromium 4 mg of 19% Vanadyl Sulfate, 100 mg of 56% magnesium oxide, 99mg of 20% potassium citrate, 2.5 mg of 1 8% manganese ascorbate, 12.5 mg of 80% zinc oxide, and .5 mg of 10% copper chelate.
  • an extract of cinnamon can actually revitilize the body's ability to be far more responsive to insulin in peripheral tissues, e.g. adipose and muscle tissue.
  • peripheral tissues e.g. adipose and muscle tissue.
  • glucose processing was increased by up to 20 times.
  • the chemical responsible is called methylhydroxy
  • mice found that abnormally high glucose concentrations fell dramatically when given this cinnamon derivative.
  • Gymnema sylvestre extracts doubled the number
  • Gynema sylvestre also increases the activity of enzymes responsible for glucose uptake and utilization.
  • Several other animal studies have also confirmed the blood sugar lowering effects of this compound.
  • Alpha lipoic acid has been shown to improve insulin regulated glucose disposal in animal models of insulin resistance and Type 2 diabetic patients. The data shows that Alpha lipoic acid mimics insulin action by activating the
  • Alpha lipoic acid was shown to lower blood glucose levels in diabetic animals. In addition, it enhanced glucose uptake into the peripheral tissues.
  • Vitamin B2 thiamine
  • Vitamin B2 plays an important part in the regulation of glucose metabolism and pancreatic beta cell functioning.
  • Vitamin B3 (niacin/nicotinamide/nicotinic acid) is also a significant factor in
  • Nicotinic acid is an enzyme that plays an important role in energy production and carbohydrate metabolism. Nicotinic acid is an enzyme that plays an important role in energy production and carbohydrate metabolism. Nicotinic acid is an
  • Nicotinamide has been shown to prevent the development of diabetes in experimental animals.
  • Biotin supplementation has been shown to enhance insulin sensitivity and
  • a chromium deficiency may be a significant underlying factor in the large number of Americans suffering from
  • chromium appear to be due to increased insulin sensitivity. Clinical studies in diabetics have shown that supplementing the diet with chromium can decrease fasting blood glucose levels, improve glucose tolerance and lower insulin levels.
  • NIDDM non-insulin dependent diabetes mellitus
  • Zinc is involved in virtually all aspects of insulin metabolism— synthesis
  • Zinc also has a protective effect against beta cell destruction. Diabetics typically excrete excessive amounts of zinc in the
  • Zinc can also influence the production of Ieptin , a satiety factor that reduces appetite and blood sugar level.
  • Supplementation of potassium yields improved insulin sensitivity, responsiveness and secretion.
  • Copper is a component, along with zinc, of one type of superoxide
  • dismutase copper/zinc/SOD. Deficiency may result in significant susceptability to free radical damage. Free radicals are thought to be involved in most degenerative diseases, including Type 2 diabetes.
  • guinea pigs a group consisting of guinea pigs, a
  • hypothalamic sensitivity Loss of hypothalamic sensitivity may give rise to

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation de complément nutritionnel visant à améliorer la régulation de la glycémie, à prévenir et à traiter la résistance à l'insuline, à prévenir et à traiter des troubles de l'insulinémie, à prévenir et à traiter le syndrome X et à réduire les complications diabétiques. Cette formulation combine des herbes, des minéraux et des vitamines connus pour réduire la résistance à l'insuline et des herbes, des minéraux et des vitamines connus pour réduire le taux de glycémie.
PCT/US2003/001786 2002-01-22 2003-01-21 Composition pour reguler la glycemie Ceased WO2003061679A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35124302P 2002-01-22 2002-01-22
US60/351,243 2002-01-22

Publications (1)

Publication Number Publication Date
WO2003061679A1 true WO2003061679A1 (fr) 2003-07-31

Family

ID=27613474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001786 Ceased WO2003061679A1 (fr) 2002-01-22 2003-01-21 Composition pour reguler la glycemie

Country Status (1)

Country Link
WO (1) WO2003061679A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027956A3 (fr) * 2007-08-31 2009-05-22 Shannon Minerals Patents Ltd Composition destinée au syndrome métabolique et procédé de réduction de la pression sanguine et de l'indice glycémique
US20140227371A1 (en) * 2011-07-13 2014-08-14 Alan David Heath Edible composition
CN105658093A (zh) * 2013-08-26 2016-06-08 刘新丰 用于预防和治疗第2型糖尿病的营养品组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360596A (en) * 1979-08-20 1982-11-23 Boehringer Mannheim Gmbh Process for the preparation of cholesterol esterase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360596A (en) * 1979-08-20 1982-11-23 Boehringer Mannheim Gmbh Process for the preparation of cholesterol esterase

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027956A3 (fr) * 2007-08-31 2009-05-22 Shannon Minerals Patents Ltd Composition destinée au syndrome métabolique et procédé de réduction de la pression sanguine et de l'indice glycémique
US20140227371A1 (en) * 2011-07-13 2014-08-14 Alan David Heath Edible composition
CN105658093A (zh) * 2013-08-26 2016-06-08 刘新丰 用于预防和治疗第2型糖尿病的营养品组合
EP3038474A4 (fr) * 2013-08-26 2017-03-08 Charles H. Liu Combinaison nutraceutique pour la prévention et le traitement du diabète de type 2
CN107115414A (zh) * 2013-08-26 2017-09-01 刘新丰 用于预防及治疗第2型糖尿病的营养品组合

Similar Documents

Publication Publication Date Title
US5614224A (en) Nutritional supplement for diabetics
US5730988A (en) Nutritional supplements for improving glucose metabolism
De Feo et al. Exercise and diabetes
AU2002364213B2 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US6787163B2 (en) Therapeutic treatment for blood sugar regulation
Ruan et al. Nanomedicines based on trace elements for intervention of diabetes mellitus
EP2397039A1 (fr) Compositions destinée à retarder la progression du diabète utilisant un extrait de Salacia oblonga
CN109745359A (zh) 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法
Bloomgarden International Diabetes Federation Meeting, 1997: Type 2 diabetes: its prevalence, causes, and treatment
US20230248794A1 (en) Use of mulberry extract for controlling postprandial glucose response
US20040186181A1 (en) Method and composition for decreasing ghrelin levels
EP3574912A1 (fr) Composition pour traiter une maladie diabétique
WO2003061679A1 (fr) Composition pour reguler la glycemie
US6884420B2 (en) Composition and method for reducing blood glucose
US20030039708A1 (en) Non-ma huang herb weight loss product
US20170056463A1 (en) Compositions and methods for treating diabetes
US9585898B2 (en) Method for the reduction of dangerous blood sugar levels
CN105106310A (zh) 一种用于辅助降糖的保健品
Albaser The Influence of the Concurrent Use of Catha edulis Forsk (Khat) and Empagliflozin on Dexamethasone-Induced Hyperglycemia in Rabbits
CN111214641A (zh) 一种用于治疗糖尿病的中药制剂
Gaby et al. Nutritional regulation of blood glucose
Bloomer et al. A Mixture of Glycine and Cinnamon Extract Improves Glucose Uptake and Imparts Favourable Metabolic Changes in Men and Women in Response to an Oral Glucose Load
CN106912963A (zh) 一种具有降血糖功能的小分子蛋白肽保健食品及其制备方法
WO2005072064A2 (fr) Preparation, processus et methode regenerative et technique de prevention, traitement et controle glycemique du diabete sucre
KR20070016417A (ko) 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP